Table 1.
Patient demographics including sex, cancer type (divided into subclassifications for lung cancer), type of radiation therapy, timing of immunotherapy, and exact immunotherapy used.
| DEMOGRAPHICS (n = 125) | |
|---|---|
| Men | 70 (56%) |
| Women | 55 (44%) |
| Lung cancer | 90 (72.0%) |
| • Adenocarcinoma | 59 (47.2%) |
| • Squamous cell | 24 (19.2%) |
| • Small cell | 7 (5.6%) |
| Non-lung cancer | 35 (28.0%) |
| • Melanoma | 9 (7.2%) |
| • Poorly differentiated | 4 (3.2%) |
| • Head and neck | 3 (2.4%) |
| • Neuroendocrine | 2 (1.6%) |
| • Thymic | 2 (1.6%) |
| • Other (1 case of each) | 15 (16%) |
| TYPE OF THERAPY | |
| SBRT | 68 (54.4%) |
| SRS | 57 (45.6%) |
| TIMING OF IMMUNOTHERAPY | |
| Before | 26 (20.8%) |
| After | 51 (40.8%) |
| During | 48 (38.4%) |
| IMMUNOTHERAPY | |
| Nivolumab (PD-1) | 68 (54.4%) |
| Pembrolizumab (PD-1) | 39 (31.2%) |
| Atezolizumab (PD-L1) | 16 (12.8%) |
| Avelumab (PD-L1) | 1 (0.8%) |
| Durvalumab (PD-L1) | 1 (0.8%) |
SBRT, Stereotactic Body Radiotherapy; SRS, Stereotactic Radiosurgery.